Previous
CURRENT ISSUE
№1' 2022
INFECTIOUS DISEASESInternational Medical Journal, Vol. 28., Iss. 1, 2022, P. 83−88.
DOI (https://doi.org/10.37436/2308-5274-2022-1-17)
RIBONUCLEIC ACID EFFICIENCY IN COMBINED THERAPY OF PATIENTS WITH EPSTEIN - BARR VIRUS-CAUSED INFECTIOUS MONONUCLEOSIS
V. N. Karazin Kharkiv National University, Ukraine
To evaluate the clinical and immunological efficiency of ribonucleic acid in the correction of immune disorders in patients with infectious mononucleosis caused by Epstein−Barr virus, 110 patients were examined. The surveying complex consisted of clinical and biochemical methods, enzyme−linked immunosorbent assay, polymerase chain reaction method, immunogram. According to the results of analysis of the obtained indices, in the patients with infectious mononucleosis there were revealed the changes in the system of cell and humoral links of the immune system and diversity of the immune response. The progressive nature of changes in immune parameters indicates the formation of secondary cell immune imbalance, activation of humoral link, changes in the balance of immune regulatory mediators in the direction of Th2 cells. In the acute period of the disease there were significant violations of the cell immune system, which was characterized by an increased number of cells with killer activity: mature T lymphocytes (CD3 +), cytotoxic T−suppressors (CD8 +), cells expressing the activation marker CD25 + ) and increase Th1 / Th2. Under the influence of complex immune modulatory and antiviral therapy with prescribing the ribonucleic acid, there was a positive dynamics of immunological parameters compared with patients who received only basic therapy, that was manifested by an increased proliferative response. To correct immune disorders in patients with infectious mononucleosis, it is reasonable to use Nuclex (ribonucleic acid) (250 mg 2 capsules 3 times a day) and Valacyclovir (500 mg at a dose of 1000 mg 3 times a day for 14 days). The infectious process associated with Epstein−Barr virus infection has polymorphic clinical manifestations and a large number of negative consequences, which necessitates improved clinical and laboratory diagnosis and treatment of this disease.
Key words: infectious mononucleosis, Epstein − Barr virus, immune response, antiviral and immune modulatory therapy.
REFERENCES
1. Luzuriaga K., Sullivan J. L. Infectious mononucleosis. NEJM. 2010. № 362 (21). R. 1993−2000. doi: https://doi.org/10.1056/NEJMcp1001116
2. Odumade O. A., Hogquist K. A., Balfour H. H. Progress and problems in understanding and managing primary Epstein − Barr virus infections. Clin. Microbiol Rev. 2011. № 24 (1). R. 193−209. doi: https://doi.org/10.1128/CMR.00044−10
3. Drozdova N. F., Fazylov V. Kh. Infektsionnyi mononukleoz, obuslovlennyi virusom Epshteina − Barr: klinikopatogeneticheskie aspekty (obzor literatury). Vestn. sovremennoi klinicheskoi meditsiny. 2018. № 11 (3). S. 59−61. URL: https://cyberleninka.ru/article/n/infektsionnyy−mononukleoz−obuslovlennyy−virusom−epshteyna−barr−kliniko−patogeneticheskie−aspekty−obzor−literatury. doi: https://doi.org/10.20969/vskm.2018.11(3).59−65
4. Balfour H. H. Jr., Dunmire S. K., Hogquist K. A. Infectious mononucleosis. Clin. Transl. Immunol. 2015. Vol. 4 (2). e33. doi: https://doi.org/10.1038/cti.2015.1
5. Klinicheskie proyavleniya infektsionnogo mononukleoza pri pervichnoi ili reaktivirovannoi gerpesvirusnoi infektsii / O. I. Demina i dr. Rossiiskii vestn. perinatologii i pediatrii. 2020. № 65 (1). S. 37−44. doi: https://doi.org/10.21508/1027−4065−2020−65−1−37−44
6. The role of children and adults as a reservoir of pathogens during the seasonal rise in the incidence of upper respiratory tract infections / T. V. Solomay et al. Children infections. 2020. Vol. 19 (3). P. 5−11. doi: https://doi.org/10.22627/2072−8107−2020−19−3−5−11
7. Isakov V. A., Arkhipova E. I., Isakov D. V. Gerpesvirusnye infektsii cheloveka: rukovodstvo dlya vrachei. SPb.: SpetsLit, 2013. 13 c.
8. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein − Barr virus infection in university students / H. H. Balfour et al. J. Infect. Dis. 2013. Vol. 207. P. 80−88. doi: https://doi.org/10.1093/infdis/jis646
9. Vozianova Z. H., Hley A. II. Infektsiyniy mononukleoz yak polietiolohichne zakhvoryuvannya. Suchasni infektsiyi. 2004. Vol. 2. P. 37−41.
10. The pathogenesis of Epstein − Barr virus persistent infection / D. A. Thorley−Lawson, J. B. Hawkins, S. I. Tracy, M. Shapiro. Current opinion in virology. 2013. Vol. 3 (3). P. 227−232. doi: https://doi.org/10.1016/j.coviro.2013.04.005
11. Gel'sіns'ka deklaratsіya Vsesvіtn'oї medichnoї asotsіatsії "Etichnі printsipi medichnikh doslіdzhen' za uchastі lyudini u yakostі ob'єkta doslіdzhennya". 2008. URL: http://zakon2.rada.gov.ua/laws/show/990_005